Contract Deobligations Alert — June 17, 2026

TOTE Services' $309.6M firm-fixed-price delivery order from the Maritime Administration is 85% funded ($264.2M outlayed), reducing future payment risk and providing multi-year revenue visibility through August 2029.

Kiewit's $103.3M firm-fixed-price contract for Yosemite wastewater treatment plant replacement transfers cost overrun risk to the contractor, with no options and full obligation at award, compressing margins.

Leidos' $126.4M cost-plus-fixed-fee delivery order from NIH NCI for GOCO R&D facility management has a fixed end date (August 2024) and $52.2M remaining, limiting upside beyond the current period.

TOTE Services' $309.6M firm-fixed-price vessel contract carries cost overrun risk over a multi-year performance period (through August 2029), with only 85% funded, leaving $45.4M at risk if delays or overruns occur.

Kiewit Infrastructure West Co.'s $103.3M firm-fixed-price wastewater treatment plant replacement at Yosemite has high execution risk due to complex construction and long duration (5.5 years), with no options to adjust scope.

Leidos Biomedical Research Inc.'s $126.4M NIH GOCO facility contract has a fixed end date (August 2024) with no options, creating a potential revenue cliff for Leidos' federal R&D services segment.

TOTE Services' $309.6M NSMV V vessel award positions the company for follow-on NSMV or similar vessel contracts from the Maritime Administration, given the fully funded and competitive award structure.

Kiewit Infrastructure West Co.'s $103.3M NPS contract signals stable infrastructure spending in national parks, with potential for follow-on awards as the Department of the Interior continues to invest in large projects.

Two of three contracts (TOTE Services' $309.6M vessel and Kiewit's $103.3M wastewater plant) are civilian infrastructure awards, reflecting stable government investment in specialized vessel construction and national park facilities.

Leidos Biomedical Research Inc.'s $126.4M NIH GOCO facility contract reinforces Leidos' position in federal life sciences R&D support, but the fixed end date limits upside.

{"entity"=>"TOTE Services", "reason"=>"TOTE Services' $309.6M NSMV V contract is 85% funded, but the remaining $45.4M and fixed-price structure create execution risk; watch for cost overrun disclosures or modifications.", "trigger"=>"Contract modifications or quarterly earnings reports on NSMV V progress"}

{"entity"=>"Leidos Holdings", "reason"=>"Leidos Biomedical Research Inc.'s $126.4M NIH GOCO facility contract ends August 2024 with no options, creating a potential revenue cliff; watch for follow-on awards or extensions.", "trigger"=>"NIH NCI budget appropriations for FY2024 or re-compete announcements"}

{"entity"=>"Kiewit Infrastructure West Co.", "reason"=>"Kiewit's $103.3M fixed-price NPS contract has high execution risk; watch for project cost overruns or delays that could impact margins.", "trigger"=>"Quarterly earnings mentions of project delays or cost overruns"}